Array Biopharma Inc.

Takeda Pharmaceutical Company Limited

Christopher Peter Corrette

Robert Kirk Delisle

George A Doherty

Laurence Edward Burgess

Adam Wade Cook

Albert Charles Gyorkos

Kevin W Hunt

Christopher T Clark

Todd T Romoff

Joseph P Lyssikatos

Eli M Wallace

Qian Zhao

Shelley Allen

Ellen Ruth Laird

John E Robinson

Jeremy J Hans

Ganghyeok Kim

Scott Alan Pratt

Kazuyoshi Aso

Robert Kirk DeLisle

Suk Young Cho

Walter C Voegtli

Tsuneo Yasuma

Masato Yoshida

Hiroyuki Kimura

Masakuni Kori

Michiyo Mochizuki

Akira Mori

Masahiro Kawase

Christopher Stephen Siedem

Timothy Mark Turner

Steven Armen Boyd

Kevin Ronald Condroski

Walter C Voegtil

Michiyo Gyoten

Provided herein are compounds of Formula I: in which A, A, W, L, G, R, R, R, Rand Rhave the meanings given in the specification, which are DP2 receptor modulators useful in the treatment of immunologic diseases.

6-substituted phenoxychroman carboxylic acid derivatives

There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; Xis CR, CRR, N or NR; Xis N or NR; Y is C, CRor N, Z is CR, CRR, N or NR; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; andis a single bond or a double bond; R, R, R, R, R, R, Rand Rare independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CRor N; R, R, R, Rand Rare independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X, R, R, Y and Xin formula (II) and (III) as before.

Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.

Mitotic kinesin inhibitors and methods of use thereof

Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A, A, W, L, G, R, R, R, Rand Rare as defined herein.

Compounds of Formula I: (I) in which A, A, R, R, R, Rand Rhave the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D(PGD). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13. 

7-phenoxychroman carboxylic acid derivatives

A compound having the formula: is useful in the preparation of compounds of Formula I.

Compounds of Formula (I): in which A, A, W, L, G, R, R, R, Rand Rhave the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases. 

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or &#x2014;NR&#x2014; (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, &#x2014;CO&#x2014;, oxygen, sulfur, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;NR&#x2014;, &#x2014;NR-alk-, &#x2014;CONR&#x2014; or &#x2014;NRCO&#x2014; (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.

Fused heterocyclic compounds

There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W&#x2014;Ar&#x2003;&#x2003;(I) 

Cyclic compounds

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and Xis an oxygen, a sulfur or &#x2014;NR&#x2014;, or formula (A&#x2033;): wherein X is a nitrogen and Ris an optionally substituted hydrocarbyl, Ris an amino substituted by two optionally substituted hydrocarbyl groups, Ris an phenyl, Yis CRor a nitrogen, Yis CRor a nitrogen and Yis CRor a nitrogen, provided that one or less of Y, Y, and Yis nitrogen, W is a bond, &#x2014;(CH)n-, and Z is a bond, &#x2014;NR&#x2014;, etc.; or a salt thereof or a prodrug thereof.

Nitrogen-containing fused heterocyclic compounds

There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; Xis CR, CRR, N or NR; Xis N or NR; Y is C, CRor N, Z is CR, CRR, N or NR; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and&#x2009;is a single bond or a double bond; R, R, R, R, R, R, Rand Rare independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CRor N; R, R, R, Rand Rare independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X, R, R, Y and Xin formula (II) and (III) as before.

Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents

Growing community of inventors

Boulder, CO, United States of America

Christopher Peter Corrette